| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Wang,Yao-Qian | Chairman | 10.30% | JI CHUANG Co., Ltd. |
| Wang,Shu-Xin | Director | 3.81% | QIAO YE Co., Ltd. |
| Huang,Guo-Liang | Director | 1.56% | GREAT UNITED STRONG ENTERPRISE CO., LTD. |
| Li,Yi-Qi | Independent Director | 0.00% | |
| Xu,Qian-Yi | Independent Director | 0.00% | |
| Wang,Xiu-Mei | Independent Director | 0.00% | |
| Li,Yue-Yang | Independent Director | 0.00% |
Change Company Name to AMED CO., LTD.
2024/05/30
Change Capital to 1,000,000,000
2023/06/13
Change Company Name to AMED BIOMEDICAL CO., LTD. (FORMER NAME: INTERUI BIOMEDICAL CO., LTD.)
2022/09/12
Change Capital to 350,000,000
2019/04/08
Change Person in Charge to Wang,Yao-Qian
2018/04/13
Change Company Name to AMED CO., LTD.
2017/12/19
Change Capital to 300,000,000
2016/07/27
Change Capital to 90,000,000
2016/05/19
Change Capital to 80,000,000
2016/05/02
Change Capital to 70,000,000
2016/03/11
Change Capital to 60,000,000
2016/01/11
Change Capital to 50,000,000
2015/12/17
Change Capital to 40,000,000
2015/08/31
Change Capital to 30,000,000
2015/08/20
Change Capital to 20,000,000
2015/06/11
Change Person in Charge to Wang,Shu-Xin
2013/11/21
下載完整報告查看完整數據
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 389,359 | 763,823 | 689,649 |
| Operating cost | 129,394 | 239,266 | 193,711 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 259,965 | 524,557 | 495,938 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 259,965 | 524,557 | 495,938 |
| Operating expenses | 205,196 | 401,272 | 383,809 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 54,769 | 123,285 | 112,129 |
| Non-operating income and expenses | -653 | -1,054 | -6,773 |
| Net profit (loss) before tax | 54,116 | 122,231 | 105,356 |
| Income tax expense (benefits) | 13,123 | 30,515 | 28,106 |
| Net profit (loss) of ongoing business for the current period | 40,993 | 91,716 | 77,250 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 40,993 | 91,716 | 77,250 |
| Other comprehensive profit (loss), net | - | - | - |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 40,993 | 91,716 | 77,250 |
| Net profit (loss) attributable to owners of parent company | - | - | - |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | - | - | - |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 1 | 3 | 3 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | - | - | - |
| Net cash inflows (outflows) from investing activities | - | - | - |
| Net cash inflow (outflow) from financing activities | - | - | - |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | - | - | - |
| Beginning balance of cash and cash equivalents | - | - | - |
| Ending balance of cash and cash equivalents | - | - | - |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 519,263 | 453,104 | 406,098 |
| Non-current asset | 489,994 | 432,747 | 420,418 |
| Total asset | 1,009,257 | 885,851 | 826,516 |
| Current liability | 356,207 | 270,136 | 297,237 |
| Non-current liability | 261,018 | 189,676 | 194,973 |
| Total liability | 617,225 | 459,812 | 492,210 |
| share capital | 300,000 | 300,000 | 240,000 |
| Equity - secruity token | - | - | - |
| capital reserve | 458 | 458 | 441 |
| retained earning | 91,574 | 125,581 | 93,865 |
| Other equity | 0 | 0 | 0 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | - | - | - |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 392,032 | 426,039 | 334,306 |
| Share capital awaiting retirement (unit: share) | - | - | - |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 13 | 14 | 13 |
